Almetec to be exposed to fiercer competition

Published: 2011-02-24 07:00:00

Updated: 2011-02-24 07:00:00

Daiichi-Sankyo’s Almetec (olmesartan medoxomi), a selective AT1 subtype angiotensin II receptor antagonist, will not be stable in 2014, as a growing number of Korean pharmaceutical companies are poised to enter a 90 billion Almetec market here.

Currently, a great number of domestic drug manufa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK